| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
,25-Dihydroxyvitamin D3 with Dexamethasone Enhances Cell Cycle Arrest and Apoptosis
Departments of Pharmacology [R. J. B., W-D. Y., T. F. M., P. A. H., C. S. J.], Medicine [D. L. T., C. S. J.], and Urology [D. L. T.], University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213
Previously we have shown that dexamethasone (DEX) enhances the antitumor activity and ligand binding of the active form of vitamin D, 1
,25-dihydroxyvitamin D3 (1,25-D3), in the murine squamous cell carcinoma model SCC VII/SF. DEX also reduces the hypercalcemia toxicity of 1,25-D3 treatment. However, the mechanism of the enhanced antitumor activity has not been defined. Here, we demonstrate that both cell cycle arrest and apoptosis were enhanced by DEX, effects that were inhibited by RU486. We also demonstrate that vitamin D receptor (VDR) protein levels were increased by the combination of 1,25-D3 and DEX above the level observed with 1,25-D3 treatment alone, whereas protein levels of the heterodimeric partner of VDR, retinoid X receptor, were lower for the combination than for 1,25-D3 alone. Glucocorticoid receptor protein levels and ligand binding were increased by 1,25-D3 but not by the combination. Treatment with the combination of 1,25-D3 and DEX did not result in greater activation of a vitamin D response element-reporter than 1,25-D3 alone or of a glucocorticoid response element-reporter than DEX alone. Nevertheless, the levels of phospho-Erk1/2 and phospho-Akt, signaling molecules that are modulated in 1,25-D3-treated squamous cell carcinoma cells, were reduced by the combination of 1,25-D3 and DEX more than by either agent alone. These trends were also observed in vivo. Our results suggest the involvement of the Erk and Akt signaling pathways in the antiproliferative effects of the combination of 1,25-D3 and DEX and that phospho-Erk1/2 and phospho-Akt may be useful markers of response to this combination.
This article has been cited by other articles:
|
|
 |
|
  A. Myrthue, B. L.S. Rademacher, J. Pittsenbarger, B. Kutyba-Brooks, M. Gantner, D. Z. Qian, and T. M. Beer The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells Clin. Cancer Res., June 1, 2008; 14(11): 3562 - 3570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Hart, D. Ornelles, and C. Koumenis The Adenoviral E4orf6 Protein Induces Atypical Apoptosis in Response to DNA Damage J. Biol. Chem., March 2, 2007; 282(9): 6061 - 6067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Weber, F. C. Gaertner, W. Erl, K.-P. Janssen, B. Blechert, B. Holzmann, H. Weighardt, and M. Essler IL-22-Mediated Tumor Growth Reduction Correlates with Inhibition of ERK1/2 and AKT Phosphorylation and Induction of Cell Cycle Arrest in the G2-M Phase J. Immunol., December 1, 2006; 177(11): 8266 - 8272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ma, W.-D. Yu, R.-X. Kong, D. L. Trump, and C. S. Johnson Role of Nongenomic Activation of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathways in 1,25D3-Mediated Apoptosis in Squamous Cell Carcinoma Cells Cancer Res., August 15, 2006; 66(16): 8131 - 8138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Beer, M. Javle, G. N. Lam, W. D. Henner, A. Wong, and D. L. Trump Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer Clin. Cancer Res., November 1, 2005; 11(21): 7794 - 7799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Hart, S. M. Yannone, C. Naczki, J. S. Orlando, S. B. Waters, S. A. Akman, D. J. Chen, D. Ornelles, and C. Koumenis The Adenovirus E4orf6 Protein Inhibits DNA Double Strand Break Repair and Radiosensitizes Human Tumor Cells in an E1B-55K-independent Manner J. Biol. Chem., January 14, 2005; 280(2): 1474 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Beer and A. Myrthue Calcitriol in cancer treatment: From the lab to the clinic Mol. Cancer Ther., March 1, 2004; 3(3): 373 - 381. [Abstract] [Full Text]
|
|
|
|
|
|
H. Wang, M. Li, J. J. Rinehart, and R. Zhang Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: In Vivo Activity, Pharmacokinetics, and Clinical Implications for Cancer Chemotherapy Clin. Cancer Res., March 1, 2004; 10(5): 1633 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Crescioli, P. Ferruzzi, A. Caporali, R. Mancina, A. Comerci, M. Muratori, M. Scaltriti, G. B. Vannelli, S. Smiroldo, R. Mariani, et al. Inhibition of Spontaneous and Androgen-Induced Prostate Growth by a Nonhypercalcemic Calcitriol Analog Endocrinology, July 1, 2003; 144(7): 3046 - 3057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sundaram, A. Sea, S. Feldman, R. Strawbridge, P. J. Hoopes, E. Demidenko, L. Binderup, and D. A. Gewirtz The Combination of a Potent Vitamin D3 Analog, EB 1089, with Ionizing Radiation Reduces Tumor Growth and Induces Apoptosis of MCF-7 Breast Tumor Xenografts in Nude Mice Clin. Cancer Res., June 1, 2003; 9(6): 2350 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Danilenko, Q. Wang, X. Wang, J. Levy, Y. Sharoni, and G. P. Studzinski Carnosic Acid Potentiates the Antioxidant and Prodifferentiation Effects of 1{alpha},25-Dihydroxyvitamin D3 in Leukemia Cells but Does Not Promote Elevation of Basal Levels of Intracellular Calcium Cancer Res., March 15, 2003; 63(6): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Beer, K. M. Eilers, M. Garzotto, M. J. Egorin, B. A. Lowe, and W. D. Henner Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer J. Clin. Oncol., January 1, 2003; 21(1): 123 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Bernardi, C. S. Johnson, R. A. Modzelewski, and D. L. Trump Antiproliferative Effects of 1{alpha},25-Dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-Derived Endothelial Cells Endocrinology, July 1, 2002; 143(7): 2508 - 2514. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
